Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.
Is Reata Pharmaceuticals a good stock to buy?
Reata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is Reta stock a buy?
3% Minimum Coupon Principal Protected Based Upon Russell is very positive about RETA and gave it a "Buy" rating on May 26, 2021.
